35 results on '"Ghany, Marc G."'
Search Results
2. Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B
3. The Hepatitis B Vaccine Protects Re-Exposed Health Care Workers, But Does Not Provide Sterilizing Immunity
4. Su1336: TREATMENT INITIATION AND OUTCOMES OF AFRICAN AMERICANS AND NON-AFRICAN AMERICANS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION
5. Mo1571 COMPARISON OF PERFORMANCE CHARACTERISTICS OF COMMERCIALLY AVAILABLE ASSAYS FOR HEPATITIS D
6. Mo1570 DEFYING DANGER: ASSESSING OLOROFIM'S IMPACT ON THE LIVER - A CASE REPORT OF SEVERE DILI AND SUCCESSFUL RECHALLENGE
7. 1063 INCIDENCE AND FACTORS ASSOCIATED WITH HEPATITIS B SURFACE ANTIGEN LOSS IN A MULTIETHNIC COHORT OF CHRONIC HEPATITIS B PATIENTS
8. Maintenance Peginterferon Therapy and Other Factors Associated With Hepatocellular Carcinoma in Patients With Advanced Hepatitis C
9. S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders
10. Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling
11. Factors That Determine the Development and Progression of Gastroesophageal Varices in Patients With Chronic Hepatitis C
12. Predicting Clinical and Histologic Outcomes Based on Standard Laboratory Tests in Advanced Chronic Hepatitis C
13. Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alfa–Dependent Manner
14. Effect of HCV RNA Suppression During Peginterferon Alfa-2a Maintenance Therapy on Clinical Outcomes in the HALT-C Trial
15. Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease
16. Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial
17. Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy
18. Impact of Reducing Peginterferon Alfa-2a and Ribavirin Dose During Retreatment in Patients With Chronic Hepatitis C
19. Roles of Iron and HFE Mutations on Severity and Response to Therapy During Retreatment of Advanced Chronic Hepatitis C
20. 382 ASSOCIATION BETWEEN IMMUNOHISTOCHEMICAL STAINING FOR HBV ANTIGENS IN LIVER BIOPSIES AND CIRCULATING HBV DNA AND OTHER CHARACTERISTICS OF HBV VIRAL INFECTION
21. 742 ACTIVE HBV TRANSCRIPTION AND TRANSLATION PERSIST DESPITE SUPPRESSION OF VIRAL REPLICATION IN HIV/HBV CO-INFECTED PATIENTS RECEIVING DUALLY ACTIVE ANTIRETROVIRAL THERAPY
22. Peginterferon Alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment 1,2,3
23. Progression of fibrosis in chronic hepatitis C
24. Sa1486 - Modeling Histologic and Biochemical Improvements of Disease Severity in Chronic Hepatitis B Patients Treated with Long Term Nucleoside Analogues for Up to 18 Years and the Utility of Non-Invasive Biomarkers
25. Mo1470 - The Relationship of Quantitative Hepatitis B Surface Antigen (QHBSAG) and E Antigen (Qhbeag) Levels to Liver Histology in HBV-HIV Coinfection: Results from the HBV-HIV Cohort Study
26. Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Coinfected with Human Immunodeficiency Virus (HIV)
27. Kinetics of Hbsag Loss in Nucleoside Analogue and Interferon Therapies
28. Pattern of Hepatitis B Virus (HBV) Core Antigen (HB CAG +) and Surface Antigen (HBSAG) Staining in Patients Co-Infected with Human Immunodeficiency Virus (HIV)
29. Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B
30. Sa1029 Retrospective Safety Analysis of Trainee-Performed Liver Biopsies at the National Institutes of Health Clinical Center - A 35-Year Experience
31. 900 - Pattern of Hepatitis B Virus (HBV) Core Antigen (HBCAG+) and Surface Antigen (HBSAG) Staining in Patients Co-Infected with Human Immunodeficiency Virus (HIV)
32. 350 - Kinetics of Hbsag Loss in Nucleoside Analogue and Interferon Therapies
33. 99 - Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Coinfected with Human Immunodeficiency Virus (HIV)
34. Building Bridges and Providing Transparency to the Hepatitis C Virus Drug Approval Process
35. False pasitive results using commercial RT-PCR for hepatitis C virus (HCV) RNA: frequency and impact on clinical management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.